Swiss drugmaker Roche on Friday won U.S. Food and Drug Administration (FDA) approval of its immunotherapy Tecentriq for triple-negative breast cancer, an aggressive form of the disease that has proven tough-to-treat.
Pharmamarketeer richt zich op marketingprofessionals van farmaceuten en andere medisch-gerelateerde organisaties in Nederland en België.
Copyright 2023 © Uitgave van MedHealth Communications BV | Privacy disclaimer
